II. Indications
-
HIV Infection (part of combination therapy)
- Treatment-experienced patients
- Limited use in clinical practice
III. Mechanism
IV. Dosing: Enfuvirtide
-
General
- Used in combination with other HIV Antiretrovirals
- Rotate injection sites in the upper arm, anterior thigh and Abdomen
- Avoid reinjecting sites of active cutaneous reaction
- Injection kits include all supplies (90 mg enfuviritide per vial, sterile water, syringes)
- Prepare injection by reconstituting powder in 1.1 ml sterile water diluent
- Let stand until dissolves, up to 45 minutes (do not shake)
- Adult
- Inject 90 mg SQ twice daily
- Child (age 6 to 16 years old)
- Inject 2 mg/kg (max 90 mg) SQ twice daily
V. Adverse Effects
- Injection site pain and reaction (common)
- Eosinophilic Hypersensitivity Reaction (<1%)
- Neutropenia
- Increased risk of Bacterial Pneumonia
VI. Safety
- Avoid in Lactation
- Unknown safety in pregnancy (pregnancy registry exists)
VII. Resources
Images: Related links to external sites (from Bing)
Related Studies
Definition (NCI) | A short polypeptide with activity against human immunodeficiency virus (HIV). Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 viral envelope glycoprotein, thereby preventing conformational changes required for fusion of viral and cellular membranes and preventing the virus from entering a host cell. |
Concepts | Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129) |
MSH | C105196 |
SnomedCT | 398902008, 409127007 |
LNC | LP157324-7, MTHU045714 |
English | enfuvirtide (medication), enfuvirtide [Chemical/Ingredient], Enfuvirtida, Enfuvirtide (product), Enfuvirtide, Enfuvirtide (substance), ENFUVIRTIDE, enfuvirtide, pentafuside |
Spanish | enfuvirtida (producto), enfuvirtida, enfuvirtide, enfuvirtida (sustancia) |
Ontology: HIV Fusion Inhibitors (C0949573)
Definition (MSH) | Inhibitors of the fusion of HIV to host cells, preventing viral entry. This includes compounds that block attachment of HIV ENVELOPE PROTEIN GP120 to CD4 RECEPTORS. |
Concepts | Pharmacologic Substance (T121) |
MSH | D023581 |
French | Inhibiteurs de fusion du VIH |
Swedish | HIV-fusionshämmare |
English | HIV FUSION INHIB, HIV CELL FUSION INHIB, FUSION INHIB HIV, HIV fusion inhibitor, HIV fusion inhibitors, HIV Fusion Inhibitors, Fusion Inhibitors, HIV, HIV Cell Fusion Inhibitors, HIV Fusion Protein Inhibitors |
Czech | HIV - inhibitory fúze |
Finnish | HIV:n fuusioestäjät |
Russian | SLIIANIIA VICH INGIBITORY, VICH SLIIANIIA INGIBITORY, ВИЧ СЛИЯНИЯ ИНГИБИТОРЫ, СЛИЯНИЯ ВИЧ ИНГИБИТОРЫ |
Japanese | 融合阻害剤-HIV, 融合阻害物質-HIV, HIV融合阻害剤, HIV融合阻害物質 |
Italian | Inibitori di fusione cellulare HIV, Inibitori di fusione HIV |
Polish | Inhibitory fuzji HIV |
German | Fusionsinhibitoren, HIV-, HIV-Fusionsinhibitoren, HIV-Zellfusionsinhibitoren |
Portuguese | Inibidores da Fusão de HIV |
Spanish | Inhibidores de Fusión de VIH |